Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities.

The team watched the adults with intellectual disability for one full year.

Three groups took different pills every day: metoclopramide for stomach trouble, common antipsychotics, or no meds at all.

Each month a nurse scored each person for tardive dyskinesia (TD) using the DISCUS tool.

over the study period the metoclopramide group and the antipsychotic group had the same TD rate.

Both drug groups showed more mouth, tongue and hand twitches than the no-meds group.

In plain words, the stomach drug carried the same movement risk as the psych drug.

Reberg et al. (1979) saw that stopping chlorpromazine helped some clients and hurt others. Their small reversal study warned us that med effects vary by person, which matches L et al.'s finding that not every client on metoclopramide got TD.

Shepherd et al. (2021) looked at older autistic adults on Medicare. They showed that people with ID carry heavier neurological side-effect burdens as they age. L et al. now tells us one reason why: drugs given for simple GI issues can seed future movement disorders.

Lawer et al. (2009) ran an RCT and learned antipsychotics were not cost-effective for challenging behaviour. L et al. adds a medical reason to avoid these drugs when you can: even a stomach med can trigger the same long-term brain side effect.

If a client with ID gets metoclopramide for reflux or slow gut, you now know to watch for lip smacking, tongue thrusts or finger flicks. Ask the doctor if simpler fixes like diet change, smaller meals or positioning can replace the drug. If the med is truly needed, train staff to run a quick DISCUS check each month so TD is caught early and the dose can be stopped or lowered before the movements become permanent.